Studies related to Lymphocyte Count and Lactobacillus reuteri

Safety And Tolerance Of Lactobacillus Reuteri Supplementation To A Population Infected With The Human Immunodeficiency Virus

Effect None
Trial Design Double blind
Trial Length 2-4 Weeks
Number of Subjects 39
Gender Both Genders
Age Range 18-29, 30-44, 45-64
Body Types Average
Notes for this study:
Supplementation of _l. reuteri_ at 10^10^ CFU in two divided doses a day for three weeks in persons with HIV failed to significantly influence any observed biochemical parameter to a level which was deemed practically relevant, with most parameters also failing to be significantly influenced.

Safety And Tolerability Of Lactobacillus Reuteri DSM 17938 And Effects On Biomarkers In Healthy Adults: Results From A Randomized Masked Trial

Effect None
Trial Design Double blind
Trial Length 1-6 months
Number of Subjects 31
Gender Both Genders
Age Range 30-44
Body Types Overweight
Notes for this study:
In otherwise healthy adults given _l. reuteri_ DSM 17938 at 5x10^8^ CFU daily for two months was not associated with any severe side-effects and was well tolerated. Increases in fecal _l. reuteri_ were minimal in this study and not significantly different than placebo, and immune parameters (lymphocytes, monocytes, dendritic cells) were unaffected.